Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Chinese Regulators Accept Tenelia for Review
September 25, 2019
- Astellas’ AML Drug Gets European Panel Backing
September 25, 2019
- Mylan to Distribute Eisai’s Cancer Treatment Halaven under Brand Name of Teceris in India
September 24, 2019
- Kyoto Univ. Spinout Boots Up to Develop iPSC-Based Kidney Therapy
September 24, 2019
- Mitsubishi Tanabe to Join Promotion for Santen’s Alesion Eye Drops
September 24, 2019
- Kissei Kicks Off Japan PIII for ITP Drug Fostamatinib
September 24, 2019
- SanBio’s Lead Cell Therapy Rides High with FDA’s RMAT Designation for Traumatic Brain Injury
September 20, 2019
- JCR Drops Temcell Submission for Epidermolysis Bullosa
September 20, 2019
- Kyowa Kirin to Keep Challenging to Boost Global Footprint: President
September 20, 2019
- Japan’s 1st Forteo Biosimilar Nears Market, Mochida Looks at Billion-Yen Sales
September 19, 2019
- US FDA Gives 1st Nod for Lenvima/Keytruda Combo as 2nd-Line Therapy for Endometrial Carcinoma
September 19, 2019
- GSK Launches Clinical Research of Platform for Prevention of COPD Exacerbations
September 19, 2019
- Luring Big Pharma with GPCR Work, Sosei Heptares Treads Its Own Path to Pursue Small Molecule Targets
September 18, 2019
- No Major Impact on Shionogi, Eisai from Purdue’s Bankruptcy Filing
September 18, 2019
- Fujifilm Grabs Rights to Cynata’s Cell Therapy for GVHD
September 18, 2019
- Enfortumab Vedotin Gets FDA Priority Review for Urothelial Cancer: Astellas/Seattle Genetics
September 18, 2019
- Mitsubishi Tanabe Grants Daiichi Sankyo Commercialization Rights for Edaravone in Brazil
September 18, 2019
- Astellas Ventures into Medical Device Arena with Iota Deal
September 17, 2019
- Japan Still in Transition towards Comprehensive Genomic Profiling, Health Coverage Would Expand: Chugai Official
September 17, 2019
- Eisai, Biogen Drop PIII Studies for Elenbecestat
September 17, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…